Pharmaceutical News

RSS

PPRT publishes study that evaluates pharmacist provision of clozapine

According to a study which evaluated alternative models for the delivery of clozapine services, published by the Pharmacy Practice Research Trust (PPRT), there is scope to review the team configurations needed to deliver community services in a cost-effective manner and to provide opportunities for improving the services provided to patients.

31 Oct 2011

GC-C agonists have potential to delay progression of colitis into colon cancer

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that poster P409 presented at the upcoming 2011 annual scientific meeting of the American College of Gastroenterology highlights the potential use of guanylate cyclase-C agonists to delay progression of colitis into colon cancer.

31 Oct 2011

Pacira's third quarter total revenues decrease to $4.0 million

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2011 and provided an update on the U.S. Food and Drug Administration's (FDA) approval of EXPAREL and the commercial strategy to support the product launch.

31 Oct 2011

Astex to present data on direct acting antiviral agents against HCV at 62nd AASLD meeting

Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics, announced that it will present data on its novel, first-in-class direct acting antiviral agents (DAA) against Hepatitis C Virus (HCV) at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

31 Oct 2011

FDA approves Pacira's EXPAREL for postsurgical pain management

Pacira Pharmaceuticals, Inc. announces that the U.S. Food and Drug Administration (FDA) has approved EXPAREL 1.3% for administration into the surgical site to produce postsurgical analgesia.

31 Oct 2011

BerGenBio commences preclinical development of BGB324 anti-cancer drug

BerGenBio AS, an emerging oncology biopharma, today announced it has initiated preclinical development of its proprietary lead compound, BGB324. This compound will be a first-in-class inhibitor of AXL kinase.

31 Oct 2011

Hercules Pharma granted rights to license 22nd Century's X-22 smoking cessation aid

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, announced today that the company licensed Hercules Pharmaceuticals LLC, its wholly-owned pharmaceutical subsidiary, exclusive worldwide rights to X-22.

31 Oct 2011

Study examines link between hormonal forms of contraception and sexual functioning

Today's hormonal forms of birth control are vastly different from those used by earlier generations of women, both with lower levels of hormones and with different means of delivery (not just a pill), but many of the same problems related to women's pleasure remain.

31 Oct 2011

Neutralization approach appears to prevent proliferative vitreoretinopathy

Proliferative vitreoretinopathy (PVR), or the formation of scar tissue within the eye, is a serious, sight-threatening complication in patients recovering surgical repair of retinal detachment. A new study conducted by investigators at the Schepens Eye Research Institute, the Department of Ophthalmology at Harvard Medical School, and the Massachusetts Eye and Ear Infirmary in Boston, published in the December issue of the American Journal of Pathology, suggests that a cocktail containing reagents to neutralize a relatively small subset of vitreal growth factors and cytokines may be an effective treatment.

31 Oct 2011

Renowned obstetrician receives March of Dimes 2011 Agnes Higgins award

A highly renowned obstetrician, professor and researcher who showed that babies born to obese and diabetic women have a higher risk of becoming overweight and developing diabetes or other metabolic health problems later in life, received the March of Dimes 2011 Agnes Higgins award for outstanding achievement in the field of maternal-fetal nutrition.

31 Oct 2011

New library for development of targeted cancer drugs

In a technical tour de force, scientists at Fox Chase Cancer Center have cataloged and cross-indexed the actions of 178 candidate drugs capable of blocking the activity of one or more of 300 enzymes, including enzymes critical for cancer and other diseases. Additionally, a free library of the results has been made available online to the research community. This unique library represents an important new tool for accelerating the development of an entire class of targeted cancer drugs.

31 Oct 2011

Oral hormonal contraceptives linked to blood clots: Study

A new study has shown that women who use new type of contraceptive pills are twice as likely to develop life threatening blood clots as those who take older versions. Oral hormonal contraceptives have been known to increase the risk of a blood clot in deep leg veins, known as venous thromboembolism (VTE). These can prove fatal if they travel to the lungs. But, researchers at the University of Copenhagen, Denmark, found the “third-generation” pills are doubly harmful than the older versions.

30 Oct 2011

VUMC doctors to begin statin drug screening for rare genetic variation

Vanderbilt University Medical Center doctors announced today they will begin screening patients who take commonly prescribed statin drugs for a rare genetic variation that can increase risks for side effects from these drugs such as muscle aches, kidney damage and even death.

29 Oct 2011

ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide in a pediatric sarcoma model.

29 Oct 2011

NYUCN to study 'Test and Linkage to Care Among Injecting Drug Users Kenya'

New York University College of Nursing (NYUCN) received a five-year, $4,161,665.00 grant from the National Institute of Health's National Institute on Drug Abuse (NIH/NIDA) to research "Test and Linkage to Care Among Injecting Drug Users (TLC_IDU) Kenya."

29 Oct 2011

Massachusetts court awards injunction preventing Watson from selling Amphastar's generic LOVENOX

Watson Pharmaceuticals, Inc., today confirmed that the United States District Court for the District of Massachusetts has granted Momenta Pharmaceuticals, Inc. and Sandoz Inc.'s request for a preliminary injunction preventing Watson and Amphastar Pharmaceuticals, Inc. from marketing or selling Amphastar's Enoxaparin Sodium Injection, a generic equivalent to Sanofi-aventis' LOVENOX.

29 Oct 2011

White Smile Global introduces new at-home, foaming teeth whitening product

White Smile Global Inc. introduces the White Smile Complete Oral Foam featuring Dual Oxygen-Infused Technology.

29 Oct 2011

MEDA files marketing authorization application for Dymista in Europe

The marketing authorization application for Dymista (a novel formulation of azelastine hydrochloride and fluticasone propionate) has been filed in Europe. The application uses a decentralized procedure and the reference member state is Germany.

29 Oct 2011

Preventive use of ACZ may reduce risk of severe high altitude illness

Measuring specific, exercise-related responses can help physicians determine who may be more at risk for severe high altitude illness (SHAI), according to a study conducted by researchers in France. The researchers also found that taking acetazolamide (ACZ), a drug frequently prescribed to prevent altitude illness, can reduce some of the risk factors associated with SHAI.

29 Oct 2011

EC approves Lilly's ALIMTA as continuation maintenance therapy for NSCLC

Eli Lilly and Company announced today that the European Commission has granted approval for the use of ALIMTA (pemetrexed for injection) as a single agent for continuation maintenance therapy in patients with a particular type of lung cancer, called advanced nonsquamous non-small cell lung cancer

29 Oct 2011